about
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group.High dose chemotherapy in ovarian cancer.Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialKi-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewDocetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.Sex steroid binding to human lymphocytes plasma membrane.Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancerSequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship.A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples.Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.Treatment of malignant lymphoma with high dose of chemo or chemoradiotherapy and bone marrow transplantation.6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer.Estradiol membrane binding sites on human breast cancer cell lines. Use of a fluorescent estradiol conjugate to demonstrate plasma membrane binding systems.Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer.Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.[Adjuvant treatment of colon cancer MOSAIC study's main results].Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study.Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.[Follow-up of endometrial cancer].Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.Etoposide and cisplatinum in resistant lymphomas.Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impactRecombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled studyEffectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohortClinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 studyRésection vasculaire et cancers annexiels : à propos de 2 cas
P50
Q24812405-5B5BF161-5DF4-4A89-9376-2501DFEAEB48Q33502877-BF050A99-5023-4E30-9841-A854DFB57DF0Q34328191-6DF305E7-1D24-4D37-8E5E-526BFA78EFF2Q35828693-435D144B-8C5A-4F80-9657-F2667518270CQ35904441-2367A49F-3675-4470-BA79-333061A8D3B1Q35982674-03D329BC-42A9-4FE2-8A40-2BF04F07FB55Q35991501-F813FFC8-E86A-4A2C-B374-B6ED9CBF699DQ36485454-A39F8484-E76C-4F95-9DA4-D68F11EE7398Q36644194-DC21E19F-FD12-4247-B6E2-01AF6653370AQ37421194-B657DE3D-43C6-47FF-AFB8-B911A0ACEB04Q37633920-75DF9ABC-AF8F-4D24-A44C-4FD3DB1D11CCQ38803428-AD387B8A-9008-4965-9F60-A72F1675F62FQ40365203-A7D909EE-15BC-436C-B4B9-25030AF4D149Q40531917-260563A9-E7B5-4336-B55F-E3C19A43364AQ40616446-CFB5DD35-882A-4EC1-A168-75E949D5FEC1Q40777129-B71D6BB0-566B-49C1-ABCC-982B249D3ECAQ42365795-F45C9416-7BDC-49D5-9E23-BEA2CA6354CBQ43524645-999C8365-7AEF-48D3-BE95-E77BE3BAF673Q43697526-4CF5D4FC-E450-49E7-AC38-0418C98EE058Q43784378-439895B1-F5E6-4180-95E4-2DC32D22FB70Q43824292-AFEC7620-10C8-4752-83C1-55A73757EFC3Q44238687-B6BAE70E-3A62-4107-96A5-7FFFA7852602Q44529241-7DF55942-9BC4-49CE-AECB-551538A9D935Q44583931-38D61983-3076-4A79-8C14-9CDD463DF06CQ45282927-F7C154BD-1C29-4243-A8ED-7EB0F277D93AQ46839548-00C7AA44-DEE0-4CA7-9E72-1FB327594266Q46949078-87BB1B45-AEEF-486F-933F-A7DEF5AC9CCAQ47099265-F2762741-6674-4E1D-B3FB-A8B164B105ECQ47237524-9DB73440-0AF0-47A8-A07D-D2EC30C546D0Q48628008-2E234A99-BDF8-4B14-ADA2-22ABE92055A4Q50042411-530493AA-20F8-40F8-A561-6278A33C5120Q51927016-E1E11D29-E0AE-423F-8B15-7BD7E4C96487Q53059838-4DA59A1D-5F54-4B30-B67D-25789632B07AQ53190500-C14D64EC-B814-4879-B564-1080DAC51F84Q54414044-59A2381F-2DA3-440A-836D-23827A69E804Q57579477-D0453CE5-C747-4B84-91B4-7BAD59E45218Q60685444-88FB8016-43EB-495F-BB52-73B144FFB13DQ63322442-F0EA7A20-7FE9-4A5D-B163-C178E6D9615DQ63322485-95071FDB-B741-4174-B1AF-85FB516B6288Q63322529-DFFC908F-3346-4778-AEAB-20C5C62A27C2
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicole Tubiana Mathieu
@ast
Nicole Tubiana Mathieu
@en
Nicole Tubiana Mathieu
@es
Nicole Tubiana Mathieu
@nl
Nicole Tubiana Mathieu
@sl
type
label
Nicole Tubiana Mathieu
@ast
Nicole Tubiana Mathieu
@en
Nicole Tubiana Mathieu
@es
Nicole Tubiana Mathieu
@nl
Nicole Tubiana Mathieu
@sl
prefLabel
Nicole Tubiana Mathieu
@ast
Nicole Tubiana Mathieu
@en
Nicole Tubiana Mathieu
@es
Nicole Tubiana Mathieu
@nl
Nicole Tubiana Mathieu
@sl
P106
P1153
7003400439
P21
P31
P496
0000-0001-7849-3667